
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. has significantly raised its full-year 2025 pro forma net revenue guidance to a range of $390–$410 million, reflecting robust adoption of its product, DefenCath, and anticipated contributions from the Melinta portfolio. The company projects a fourth-quarter net revenue between $115 million and $135 million, indicating a strong momentum heading into the year's end, supported by higher utilization among outpatient dialysis customers. Additionally, Cormedix reported better-than-expected performance in Q3 2025, with net revenue of $104.3 million, underscoring its positive commercial execution strategy and positioning for future growth.
Bears say
Cormedix Inc. faces potential financial challenges, particularly with expectations of a significant price drop for its product DefenCath upon the second phase of the Transitional Drug Add-on Payment Adjustment (TDAPA) in July 2026. While there is a projected market opportunity for the company's other product, Niyadas, estimated between $100 million and $200 million, the implications of TDAPA pricing uncertainties loom large over the company's revenue prospects. Additionally, the competitive landscape for catheter lock solutions, particularly against established generics like Heparin, raises concerns about DefenCath's ability to meet sales projections.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares